Summary:
- Bio Affinity Technologies, a company that develops non-invasive cancer diagnostic tests, reported record revenue of $9.4 million for the year.
- The company's CyPath® Lung test, which uses a person's breath to detect early-stage lung cancer, saw increased demand and adoption during the year.
- The successful financial performance and progress of the company's cancer detection technology indicate advancements in the field of non-invasive cancer diagnostics, which can help with early detection and improved patient outcomes.